Insider · CIK 0001103804
Viking Global Investors LP
Files at BBIO (BridgeBio Pharma, Inc.), INBX (Inhibrx Biosciences, Inc.). First filing Jan 31, 2025, latest Oct 9, 2025.
Viking Global Investors LP files SEC Form 4 as 10% owner at BBIO (BridgeBio Pharma, Inc.), and also at INBX (Inhibrx Biosciences, Inc.). Since Jan 31, 2025, Viking Global Investors LP has reported 0 open-market buys worth $0 and 3 open-market sells worth $272M, the latest filed on Oct 9, 2025.
A track record needs three past buys with six months of prices behind them; Viking Global Investors LP has 0, so none is measured yet.
The newest scored trade: sold $11M of INBX on Oct 7, 2025, filed Oct 9, 2025, scored 42 (moderate).
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
BBIO: BridgeBio Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
INBX: Inhibrx Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | INBXsell Inhibrx Biosciences, Inc. | $11M 350,000 shares | -22% | +209% from low-6% from high | |
| 57Moderate | BridgeBio Pharma, Inc. | $154M 3,500,000 shares | -16% | +101% from low-1% from high | |
| 57Moderate | BridgeBio Pharma, Inc. | $107M 3,065,616 shares | -12% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 31, 2025 | BBIO BridgeBio Pharma, Inc. | 3,065,616 1.62% of outstanding | $107M | Jan 31, 2025 | none |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 7, 2025 | INBX Inhibrx Biosciences, Inc. | SOpen-market sale Common Stockindirect: See Explanation of Responses | -308,643 | $32.25 | $10.0M | 1,267,823 | Oct 9, 2025 |
| Oct 7, 2025 | INBX Inhibrx Biosciences, Inc. | SOpen-market sale Common Stockindirect: See Explanation of Responses | -16,315 | $32.25 | $526k | 67,018 | Oct 9, 2025 |
| Oct 7, 2025 | INBX Inhibrx Biosciences, Inc. | SOpen-market sale Common Stockindirect: See Explanation of Responses | -25,042 | $32.25 | $808k | 102,864 | Oct 9, 2025 |
| Jun 27, 2025 | BBIO BridgeBio Pharma, Inc. | SOpen-market sale Common Stockindirect: See Explanation of Responses | -3,500,000 | $44.00 | $154M | 18,555,375 | Jul 1, 2025 |
| Jan 31, 2025 | BBIO BridgeBio Pharma, Inc. | SOpen-market sale Common Stockindirect: See Explanation of Responses | -3,065,616 | $34.90 | $107M | 22,055,375 | Jan 31, 2025 |
Questions about Viking Global Investors LP
Answered from the filings on this page, as of the latest one.
Is Viking Global Investors LP buying or selling?
Not in the last 12 months. Viking Global Investors LP's latest open-market trade on SEC Form 4 was sold $11M of INBX on Oct 7, 2025.
How did Viking Global Investors LP's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Viking Global Investors LP has 0.
Where does Viking Global Investors LP file Form 4?
Viking Global Investors LP has filed Form 4 at BBIO (BridgeBio Pharma, Inc.); INBX (Inhibrx Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.